News | March 27, 2013

Heart Failure 2013 LA Showcases Heart Disease Startup Technologies

First of kind technologies will be presented

Cardiobridge, VAD, heart pump, hemodynamic support

The Cardiobridge 10 French circulatory support catheter pump expands in the aorta to allows a propeller to increase blood flow in hemodynamically compromised patients.

March 27, 2013 — The Heart Failure 2013 LA meeting will include a showcase of several startup companies offering innovative new approaches to address heart and cardiovascular disease, most of them based in Southern California. The showcase starts at 5:30 p.m. at the event being held Saturday, April 6, at the Millennium Biltmore Hotel in Los Angeles.  

Companies and technologies being highlighted include:

MyoStim Pacers — www.myostimpacers.com — World's first heart failure pacemaker with ability to recruit repairative stem cells to damaged and weakened heart tissue.

Bioheart Inc. — www.bioheartinc.com — Phase III leader in applying adult muscle stem cells to treat advanced heart failure. Only cell type known to grow new contractile muscle in the depths of scar tissue.

BioPace — World's first biological pacemaker made entirely of living cells.

CoroStim — World's first vibrational energy emitting pacemaker that prevents plaque formation in high-risk coronary arteries.

BioLeonhardt — www.bioleonhardt.com — Combination electrical stimulation and multi-stage cell and gene therapy method, composition and devices for treating advanced heart failure. Featuring combined utilization of MicroRNAs, nutrient time release SDF-1, hydrogel, cardiac stem cells, iPS cells and muscle progenitor stem cells. First method under testing with up to 36 repeat injection sessions of stem cells over time via a needle catheter.

Cardiobridge — www.cardiobridge.com — Highest flow rate 10 French circulatory support catheter pump in clinical testing for acute decompensating heart failure and high-risk PCI. Data on about 30 clinical patients will be presented.

AortaCell — Method and device to treat aortic aneurysms noninvasively with an abdominal belt that delivers focal wireless electrical energy to weakened aortic wall that causes repairative autologous stem cells to home to that chosen treatment location.

EndoCell — Method and device for growing new endothelium lining of a damaged artery with a percutaneous needle catheter and endothelial progenitor cells.

MyoValve — Cell seeding method and device for heart valve leaflets invivo or invitro. Designed to reduce risk of calcification and valve replacement.

Valvublator — Percutaneous catheter device for de-calcifying heart valves so a patient may keep their own valve instead of getting an artificial implant.

HeartScore — Composite scoring system of genetic, blood and scan test results (some point of care) that are loaded into the SecondBeat wearable wristwatch for a baseline score. The watch has an infrared sensor that measures real time endothelial health. The baseline score goes up or down if the patient eats well, exercises well and is in compliance with all doctor prescribed medicines and protocols. The composite HeartScore is clearly viewable to patients to help real time guidance of their heart and cardiovascular health.

For more information: www.leonhardtventures.com, www.calxcrowdfund.com, www.laheartfailure.com

 

Related Content

Heart Failure Market to Surpass $16 Billion by 2026
News | Heart Failure| September 19, 2017
The heart failure space across the seven key markets of the U.S., France, Germany, Italy, Spain, the U.K. and Japan is...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Technavio Projects 9 Percent Global Growth for Electrophysiology Therapeutic Devices

Image courtesy of Technavio

News | EP Lab| September 11, 2017
September 11, 2017 — According to the latest market study released by Technavio, the global...
TCT 2017 late-breaking trials and studies that will be presented on the latest cardiology technology clinical trials.
Feature | September 11, 2017
September 11, 2017 — From numerous high-quality submissions, Transcatheter Cardiovascular Therapeutics (TCT) has sele
Protembis Announces Successful First-in-Human Use of  ProtEmbo Cerebral Protection System in European Trial
News | Embolic Protection Devices| September 07, 2017
Protembis GmbH announced the first clinical applications of its ProtEmbo Cerebral Protection System to complement a...
Heart Failure Patients, Clinicians Have Differing Perceptions of Risk Level
News | Heart Failure| September 06, 2017
September 6, 2017 — Physicians identified a majority of patients with advanced...
Minneapolis Heart Institute Foundation Enrolls First Patient in TRILUMINATE Tricuspid Repair Trial
News | Heart Valve Technology| September 05, 2017
Minneapolis Heart Institute Foundation announced it has enrolled the first-in-the-world patient in a clinical study to...
Israeli Hospital Completes First Implant of CORolla Heart Failure Device
News | Heart Failure| September 05, 2017
Rambam Hospital in Haifa, Israel, recently became the first to use the CORolla device from Israeli start-up company...
Overlay Init